Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

The study will compare the efficacy and safety of entrectinib with crizotinib in participants with advanced or metastatic ROS1 non-small cell lung cancer (NSCLC). The participants will self-administer oral entrectinib or crizotinib as described in the protocol and local prescribing information. Treatments will continue until progressive disease, unacceptable toxicity, death, …

ROS1
proto-oncogene tyrosine-protein kinase ros
tyrosine
crizotinib
systemic therapy
  • 0 views
  • 15 May, 2022
  • 41 locations
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to …

gilbert's syndrome
cancer
osimertinib
pemetrexed
EGFR
  • 36 views
  • 23 Mar, 2022
  • 10 locations
A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours

Despite some encouraging data, systemic treatment of CNS metastases from solid tumors remains experimental. Better knowledge on the evolving epidemiology and biology of BM are key

  • 30 views
  • 18 Oct, 2021
  • 17 locations
Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of Central Nervous System (CNS) Metastases

Stereotactic radiation therapy is an important and common method of treating brain metastases in patients with malignant disease. Today, however, there are no methods available to determine the metastasis' radiation sensitivity in advance and treatment responses can only be seen by changing of the size of the metastasis on conventional …

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

This research study is studying a drug as a possible treatment for ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). The following drug will be involved in this study : Lorlatinib

serum bilirubin level
proto-oncogene tyrosine-protein kinase ros
ROS1
EGFR
kidney function test
  • 0 views
  • 25 Feb, 2022
  • 1 location
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to evaluate efficacy and safety

metastasis
monoclonal antibodies
  • 80 views
  • 16 Feb, 2022
  • 1 location
Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma

localized intraocular phase. The advanced retinoblastoma cases with central nervous system metastasis (CNS)is associated with exceedingly poor prognosis. CNS metastasis is the main cause of death in

  • 0 views
  • 09 Sep, 2021
  • 1 location
Furmonertinib in First-line Treatment of Patients With CNS Metastatic EGFR Mutation Positive NSCLC

EGFR mutation positive advanced NSCLC patients with CNS metastases have poor prognosis, second-line furmonertinib dose at 160mg level in EGRF T790M mutation positive CNS metastatic NSCLC have

  • 0 views
  • 23 May, 2022
  • 1 location
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

Funding Source - FDA OOPD This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous system metastases). WSD0922-FU is a targeted treatment which blocks the …

gefitinib
erlotinib
pemetrexed
EGFR
gemcitabine
  • 27 views
  • 24 Mar, 2022
  • 3 locations
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread to other places in the body (metastatic). Tazemetostat, dabrafenib, and …

  • 0 views
  • 12 May, 2022
  • 3 locations